• Arrowhead Pharmaceuticals announced that Australia’s Therapeutic Goods Administration has approved REDEMPLO (plozasiran), a first-in-class siRNA therapy self-administered quarterly, as an adjunct to diet for adults with familial chylomicronemia syndrome whose triglyceride levels remain uncontrolled on standard treatments.
• This decision makes REDEMPLO the first and only approved FCS therapy in Australia, extending Arrowhead’s rare lipid disorder footprint following prior authorizations in the United States, Canada, and China and supporting broader global access for clinically diagnosed as well as genetically confirmed patients.
• We’ll now examine how REDEMPLO’s first-in-country status for a rare disease in Australia reshapes Arrowhead’s investment narrative and long-term positioning.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Arrowhead Pharmaceuticals Investment Narrative Recap

To own Arrowhead, you need to believe its RNAi platform can turn REDEMPLO and a small group of late stage cardiometabolic drugs into durable, profitable franchises. The Australian approval strengthens the near term plozasiran story, but the biggest swing factor still looks to be how quickly new launches can offset lumpy collaboration income, while the key risk is that high R&D and commercial spending outstrip emerging product revenue.

The EMA’s recent positive opinion on REDEMPLO for familial chylomicronemia syndrome in Europe ties directly into the Australian news, underlining a coordinated push to turn first in class status into broader global access. Together, these milestones sit alongside Arrowhead’s expanding Phase 3 program in severe hypertriglyceridemia as the core catalysts that could gradually reduce dependence on milestone payments and clarify the company’s long term earnings profile.

Yet beneath the optimism, investors should also be aware that concentrated bets on RNAi and a few key assets leave Arrowhead exposed if...

Arrowhead Pharmaceuticals' narrative projects $398.8 million revenue and $64.0 million earnings by 2028.

Uncover how Arrowhead Pharmaceuticals' forecasts yield a $64.08 fair value, a 14% downside to its current price.

Exploring Other Perspectives

By contrast, the most bearish analysts were modeling revenues shrinking about 33 percent a year to around US$331.3 million by 2029 and earnings dropping to roughly US$49.1 million, so if you are weighing this latest REDEMPLO approval you should recognize how far that pessimistic view leans on stricter reimbursement, tougher competition and partner risk before deciding which narrative best fits your own expectations.

Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth 14% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.